图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
不入流资讯2023-07-18 17:23
$Karyopharm(KPTI)$ Karyopharm Theraoeutics climbs 25% after securing FDA fast track designation for Selinexor for treatment of Myelofibrosis #AI_Mover#查看全文
药智网2023-08-24 15:20
来源:药智网公众号
图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-05-01 AccNo: 0001193125-18-146625 Size: 21 KBItem 2.02: Results of Operations and Financial ConditionItem 8.01: Other Events 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-05-01 AccNo: 0001193125-18-146625 Size: 21 KBItem 2.02: Results of Operations and Financial ConditionItem 8.01: Other Events 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-05-01 AccNo: 0001193125-18-146606 Size: 524 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-05-01 AccNo: 0001193125-18-146606 Size: 524 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-04-30 AccNo: 0001193125-18-143134 Size: 45 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-04-27 AccNo: 0001193125-18-138861 Size: 56 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ DEF 14A - Other definitive proxy statements Filed: 2018-04-27 AccNo: 0001193125-18-138840 Size: 519 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-04-27 AccNo: 0001193125-18-138861 Size: 56 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ DEF 14A - Other definitive proxy statements Filed: 2018-04-27 AccNo: 0001193125-18-138840 Size: 519 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-04-18,CEO,Kauffman Michael ,卖出,10000普通股, $14.79